专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2012032763A1 VANGL1 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： VANGL1肽和疫苗，包括它们
公开(公告)号：WO2012032763A1
公开(公告)日：2012-03-15
申请号：PCT/JP2011/004984
申请日：2011-09-06
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAYAMA, Gaku
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAYAMA, Gaku
IPC分类号： C07K7/06 , A61K39/00 , A61K48/00 , A61P35/00 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09
CPC分类号： A61K39/0011 , C07K14/4748
摘要： The present invention provides isolated peptides or immunogenic fragments derived from SEQ ID NO: 69 that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the afore-mentioned amino acid sequences with or without the substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions containing such peptides. The peptides of this invention find utility in the treatment of cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：69的免疫原性片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括一个或两个或几个氨基酸序列的取代，缺失或添加的前述氨基酸序列之一。本发明还提供含有这些肽的药物组合物。本发明的肽可用于治疗癌症。

22. 发明申请

WO2012023290A1 RASEF AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译： RASEF作为肿瘤标志物和癌症治疗目标
公开(公告)号：WO2012023290A1
公开(公告)日：2012-02-23
申请号：PCT/JP2011/004628
申请日：2011-08-19
申请人： ONCOTHERAPY SCIENCE, INC. , DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , A61K31/711 , A61K35/00 , A61K38/00 , C07K14/435 , C07K19/00 , C12N15/09 , C12N15/113 , G01N33/574
CPC分类号： C07K14/47 , A61K31/711 , A61K38/00 , C07K14/4748 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/574 , G01N33/57423 , G01N2500/00
摘要： The present invention is based on the finding that RASEF genes are overexpressed in cancer, and involved in cancer cell survival. The present invention is also based on the finding that RASEF interacts with ERK1/2. The present invention features methods for diagnosing cancer or assessing/determining the prognosis of a subject with cancer, using RASEF genes as diagnostic markers. The present invention also features a double-stranded molecule against a RASEF gene and inhibitory polypeptide for ERK1/2 as well as vector encoding them, a method or composition for treating and/or preventing cancer using such double-stranded molecule and inhibitory polypeptide. Also, disclosed are methods of identifying a candidate substance for treating and preventing lung cancer, using RASEF or the interaction between RASEF and ERK1/2 as molecular targets.
摘要翻译：本发明基于RASEF基因在癌症中过表达并涉及癌细胞存活的发现。本发明还基于RASEF与ERK1 / 2相互作用的发现。本发明的特征在于使用RASEF基因作为诊断标记来诊断癌症的方法或评估/确定患有癌症的受试者的预后。本发明还特征在于针对RASEF基因的双链分子和针对ERK1 / 2的抑制多肽以及编码它们的载体，使用这种双链分子和抑制性多肽来治疗和/或预防癌症的方法或组合物。此外，公开了使用RASEF或RASEF和ERK1 / 2之间的相互作用作为分子靶标来鉴定用于治疗和预防肺癌的候选物质的方法。

23. 发明申请

WO2011125139A1 CLUAP1 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： CLUAP1包括其中的肽和疫苗
公开(公告)号：WO2011125139A1
公开(公告)日：2011-10-13
申请号：PCT/JP2010/006313
申请日：2010-10-26
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C07K14/705 , C07K16/00 , C12N5/10 , C12N15/00
CPC分类号： C07K14/4748 , A61K39/0011 , G01N2333/47 , G01N2333/775
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the CLUAP1 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredient peptides derived from CLUAP1 or polynucleotides encoding the peptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from CLUAP1, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的CLUAP1基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供了含有作为活性成分的衍生自CLUAP1的肽或编码肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自CLUAP1的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

24. 发明申请

WO2011021386A1 CSTF2 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： CSTF2用于肺癌癌症治疗和诊断的目标基因
公开(公告)号：WO2011021386A1
公开(公告)日：2011-02-24
申请号：PCT/JP2010/005095
申请日：2010-08-18
申请人： ONCOTHERAPY SCIENCE, INC. , DAIGO, Yataro , TSUNODA, Takuya , NAKAMURA, Yusuke
发明人： DAIGO, Yataro , TSUNODA, Takuya , NAKAMURA, Yusuke
IPC分类号： C12Q1/68 , A61P35/00 , C07K16/30 , C12N15/09 , C12N15/113 , G01N33/50 , G01N33/53
CPC分类号： G01N33/5011 , C07K16/18 , C12N15/113 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57423
摘要： The present invention relates to the roles played by a CSTF2 gene in cancer carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the CSTF2 gene or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing cancer or assessing/determining the prognosis of a subject with lung cancer, using the over-expressed CSTF2 gene. To that end, CSTF2 may serve as a novel prognosis biomarker for cancer, particularly lung cancer. Also, disclosed are methods of screening candidate substances for treating and preventing cancer, using as an index their effect on the expression or biological activity of CSTF2.
摘要翻译：本发明涉及CSTF2基因在癌症致癌中的作用，特征在于通过对CSTF2基因施用双链分子或含有这种双链分子的组合物，载体或细胞来治疗或预防癌症的方法。本发明还涉及使用过表达的CSTF2基因来诊断癌症的方法或评估/确定患有肺癌的受试者的预后。为此，CSTF2可以作为癌症，特别是肺癌的新型预后生物标志物。此外，公开了筛选用于治疗和预防癌症的候选物质的方法，以其对CSTF2的表达或生物活性的影响作为指标。

25. 发明申请

WO2011018898A1 CDC45L AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译： CDC45L AS肿瘤标志物和癌症治疗目标
公开(公告)号：WO2011018898A1
公开(公告)日：2011-02-17
申请号：PCT/JP2010/005049
申请日：2010-08-12
申请人： ONCOTHERAPY SCIENCE, INC. , DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , C12N15/09
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57423 , G01N2333/4706 , G01N2500/02
摘要： The present invention is based on the finding that CDC45L gene and PIF1 gene are everexpressed in cancer, and involved in cancer cell survival. The present invention features methods for diagnosing cancer or assessing/determining the prognosis of a subject with cancer, using CDC45L gene and/or PIF1 gene as diagnostic markers. The present invention also features a double-stranded molecule against CDC45L gene or PIF1 gene, a method or composition for treating and/or preventing cancer using such double-stranded molecule Also, disclosed are methods of identifying a candidate compound for treating and preventing lung cancer, using CDC45L and/or PIF1 as molecular targets.
摘要翻译：本发明是基于CDC45L基因和PIF1基因在癌症中过表达，涉及癌细胞存活的发现。本发明的特征在于使用CDC45L基因和/或PIF1基因作为诊断标记物来诊断癌症的方法或评估/确定患有癌症的受试者的预后。本发明还特征在于针对CDC45L基因或PIF1基因的双链分子，使用这种双链分子治疗和/或预防癌症的方法或组合物。还公开了鉴定用于治疗和预防肺癌的候选化合物的方法，使用CDC45L和/或PIF1作为分子靶标。

26. 发明申请

WO2010131452A1 TTK PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TTK肽和疫苗，包括它们
公开(公告)号：WO2010131452A1
公开(公告)日：2010-11-18
申请号：PCT/JP2010/003166
申请日：2010-05-10
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K38/00 , A61P35/00 , C07K16/18 , C12N15/09
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/572 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTK基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有作为活性成分的衍生自TTK的肽或编码肽的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自TTK的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

27. 发明申请

WO2012157239A1 CHODL AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译：作为肿瘤标志物和癌症治疗目标
公开(公告)号：WO2012157239A1
公开(公告)日：2012-11-22
申请号：PCT/JP2012/003120
申请日：2012-05-14
申请人： ONCOTHERAPY SCIENCE, INC. , DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K31/713 , A61P35/00 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/713 , C12N15/1138 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12N2310/14 , C12N2310/531
摘要： The present invention is based on the finding that the CHODL gene are overexpressed in cancer and associated with cancer prognosis, and involved in cancer cell survival. The present invention features methods for assessing or predicting the prognosis of a subject with cancer, using CHODL gene as a prognostic marker. The present invention also features a double-stranded molecule against CHODL gene, a method or composition for treating or preventing cancer using such double-stranded molecules or vectors encoding such double-stranded molecule.
摘要翻译：本发明基于CHODL基因在癌症中过表达并与癌症预后相关并且涉及癌细胞存活的发现。本发明的特征在于使用CHODL基因作为预后标记物来评估或预测患有癌症的受试者的预后的方法。本发明还特征在于针对CHODL基因的双链分子，使用这种双链分子或编码这种双链分子的载体治疗或预防癌症的方法或组合物。

28. 发明申请

WO2012153492A1 NPTX2 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译： NPTX2作为肿瘤标志物和癌症治疗目标
公开(公告)号：WO2012153492A1
公开(公告)日：2012-11-15
申请号：PCT/JP2012/002930
申请日：2012-04-27
申请人： ONCOTHERAPY SCIENCE, INC. , DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12Q1/68 , A61K31/713 , A61P35/00 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50 , G01N33/53
CPC分类号： C12Q1/6886 , A61K31/713 , C12Q2600/158 , G01N33/57488 , G01N2333/4756
摘要： The present invention arises from the discovery that the NPTX2 gene is both specifically overexpressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing cancer, as well as monitoring, determining or assessing the prognosis of a subject with cancer, using the NPTX2 gene as a diagnostic or prognostic marker. The present invention also features a double-stranded molecule against NPTX2 gene that find utility in the context of methods and compositions for the treatment and/or prevention of cancer.
摘要翻译：本发明源于NPTX2基因在癌症中特异性过表达并涉及癌细胞存活的发现。本发明的特征在于使用NPTX2基因作为诊断或预后标记物来检测或诊断癌症以及监测，确定或评估患有癌症的受试者的预后的方法。本发明还特征在于针对NPTX2基因的双链分子，其在用于治疗和/或预防癌症的方法和组合物的上下文中发挥效用。

29. 发明申请

WO2012073459A1 TOMM34 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TOMM34肽和疫苗，包括它们
公开(公告)号：WO2012073459A1
公开(公告)日：2012-06-07
申请号：PCT/JP2011/006551
申请日：2011-11-25
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAYAMA, Gaku
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa , NAKAYAMA, Gaku
IPC分类号： C12N15/00 , A61K38/00 , A61K39/00 , A61P35/00 , A61P35/04 , A61P37/04 , C07K7/06 , C07K16/32 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/0783 , C12N5/0784 , C12N5/10 , G01N33/574
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , C07K14/705 , C12N5/0638 , C12N2501/998 , C12N2502/1114 , C12N2502/1121 , G01N33/57407
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。本发明还提供包含这些肽的药物组合物。本发明的肽可用于治疗癌症。

30. 发明申请

WO2012032764A1 TTLL4 PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： TTLL4肽和含有它的疫苗
公开(公告)号：WO2012032764A1
公开(公告)日：2012-03-15
申请号：PCT/JP2011/004987
申请日：2011-09-06
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OSAWA, Ryuji
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61P35/00 , C07K7/06 , C12N9/10
CPC分类号： C12N9/93 , A61K39/0011 , C07K14/4748 , C07K16/40
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from TTLL4 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTLL4, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTLL4基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有衍生自TTLL4的肽或编码多肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤的方法免疫，使用衍生自TTLL4的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式